Copyright
©The Author(s) 2021.
World J Clin Oncol. Aug 24, 2021; 12(8): 581-608
Published online Aug 24, 2021. doi: 10.5306/wjco.v12.i8.581
Published online Aug 24, 2021. doi: 10.5306/wjco.v12.i8.581
Organs at risk | Dose constraints |
Lungs-GTV | V20 < 37%, Mean dose < 20 Gy |
Contralateral lung-PTV | V20 < 20%, V5 < 17%, Mean dose < 8 Gy |
Ipsilateral lung | V40 < 67%, Mean dose < 36 Gy |
Heart defined as pericardial sac | Right mesothelioma V40 < 25%; Left mesothelioma V40 < 35% |
Brachial plexus | Maximum dose < 65 Gy |
Esophagus | V55 Gy < 30%; Mean dose < 34 Gy |
Stomach minus including PTV | Mean dose < 30 Gy |
Bowel | Maximum dose < maximum PTV < 55 Gy; D5 cc < 50 Gy |
Spinal cord | Maximum dose < 50 Gy |
Liver minus GTV | V30 < 45%; Mean dose < 30 Gy |
Kidneys evaluated separately | V18 < 33% (or V18 < 50%, if cannot be achieved at ≤ 33%) |
Ipsilateral kidney; Contralateral kidney | V25 < 40%; V10 < 10% |
- Citation: Luna J, Bobo A, Cabrera-Rodriguez JJ, Pagola M, Martín-Martín M, Ruiz MÁG, Montijano M, Rodríguez A, Pelari-Mici L, Corbacho A, Moreno M, Couñago F. GOECP/SEOR clinical guidelines on radiotherapy for malignant pleural mesothelioma. World J Clin Oncol 2021; 12(8): 581-608
- URL: https://www.wjgnet.com/2218-4333/full/v12/i8/581.htm
- DOI: https://dx.doi.org/10.5306/wjco.v12.i8.581